“Raw Potential” And Three Other Takeaways from NY’s Life Science Disruptors
Summary
Change like that could take decades, and for it to happen, New York needs, as Flagship Ventures partner Doug Cole said, its own Biogen, Vertex Pharmaceuticals, or Genentech—companies that grow, succeed, and contribute important drugs.It needs to overcome the looming losses of community leaders Marc Tessier-Lavigne (president of Rockefeller University) and Laurie Glimcher (dean of Weill Cornell Medical College), solve its seemingly never-ending lab space problem, and find affordable housing for its employees—particularly those coming right out of school—in one of the most expensive cities in the world.Startups like Kallyope, Petra Pharma, and Lodo Therapeutics—companies spun out of New York institutions, backed by big venture rounds, with aspirations to stay in the city—have emerged.Thanks to our speakers: Marcus at Alexandria; IBM’s Prasad Kodali; Lewis Cantley of Weill Cornell; Sean Brady of Rockefeller; Accelerator Corp. chief operating officer David Schubert; Flagship partner Doug Cole; Kallyope CEO Nancy Thornberry; Charles Zuker of Columbia University; and Adam Goulburn of Lux Capital.Sean Brady formed Lodo Therapeutics in January with the help of $17 million from Accelerator Corp. and The Bill & Melinda Gates Foundation—and truth be told, he says, “I should’ve done it about three or four years ago,” given how fast the competition moves in science.
Classifications
AskAI Classifications
LabelsLinked Companies
